Pharmacologic inhibition of protein phosphatase-2A achieves durable immune-mediated antitumor activity when combined with PD-1 blockade

Protein phosphatase 2A (PP2A) has been proposed as a target for cancer immunotherapy. Here the authors show that pharmacological inhibition of PP2A with a clinically-relevant inhibitor enhances response to immune checkpoint blockade in pre-clinical models of cancer, resulting in long lasting immunit...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Winson S. Ho, Herui Wang, Dominic Maggio, John S. Kovach, Qi Zhang, Qi Song, Francesco M. Marincola, John D. Heiss, Mark R. Gilbert, Rongze Lu, Zhengping Zhuang
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2018
Materias:	Science Q
Acceso en línea:	https://doaj.org/article/fa23d329feb04210ba229907d41699e4
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:fa23d329feb04210ba229907d41699e4
record_format	dspace
spelling	oai:doaj.org-article:fa23d329feb04210ba229907d41699e42021-12-02T17:33:05ZPharmacologic inhibition of protein phosphatase-2A achieves durable immune-mediated antitumor activity when combined with PD-1 blockade10.1038/s41467-018-04425-z2041-1723https://doaj.org/article/fa23d329feb04210ba229907d41699e42018-05-01T00:00:00Zhttps://doi.org/10.1038/s41467-018-04425-zhttps://doaj.org/toc/2041-1723Protein phosphatase 2A (PP2A) has been proposed as a target for cancer immunotherapy. Here the authors show that pharmacological inhibition of PP2A with a clinically-relevant inhibitor enhances response to immune checkpoint blockade in pre-clinical models of cancer, resulting in long lasting immunity.Winson S. HoHerui WangDominic MaggioJohn S. KovachQi ZhangQi SongFrancesco M. MarincolaJohn D. HeissMark R. GilbertRongze LuZhengping ZhuangNature PortfolioarticleScienceQENNature Communications, Vol 9, Iss 1, Pp 1-15 (2018)
institution	DOAJ
collection	DOAJ
language	EN
topic	Science Q
spellingShingle	Science Q Winson S. Ho Herui Wang Dominic Maggio John S. Kovach Qi Zhang Qi Song Francesco M. Marincola John D. Heiss Mark R. Gilbert Rongze Lu Zhengping Zhuang Pharmacologic inhibition of protein phosphatase-2A achieves durable immune-mediated antitumor activity when combined with PD-1 blockade
description	Protein phosphatase 2A (PP2A) has been proposed as a target for cancer immunotherapy. Here the authors show that pharmacological inhibition of PP2A with a clinically-relevant inhibitor enhances response to immune checkpoint blockade in pre-clinical models of cancer, resulting in long lasting immunity.
format	article
author	Winson S. Ho Herui Wang Dominic Maggio John S. Kovach Qi Zhang Qi Song Francesco M. Marincola John D. Heiss Mark R. Gilbert Rongze Lu Zhengping Zhuang
author_facet	Winson S. Ho Herui Wang Dominic Maggio John S. Kovach Qi Zhang Qi Song Francesco M. Marincola John D. Heiss Mark R. Gilbert Rongze Lu Zhengping Zhuang
author_sort	Winson S. Ho
title	Pharmacologic inhibition of protein phosphatase-2A achieves durable immune-mediated antitumor activity when combined with PD-1 blockade
title_short	Pharmacologic inhibition of protein phosphatase-2A achieves durable immune-mediated antitumor activity when combined with PD-1 blockade
title_full	Pharmacologic inhibition of protein phosphatase-2A achieves durable immune-mediated antitumor activity when combined with PD-1 blockade
title_fullStr	Pharmacologic inhibition of protein phosphatase-2A achieves durable immune-mediated antitumor activity when combined with PD-1 blockade
title_full_unstemmed	Pharmacologic inhibition of protein phosphatase-2A achieves durable immune-mediated antitumor activity when combined with PD-1 blockade
title_sort	pharmacologic inhibition of protein phosphatase-2a achieves durable immune-mediated antitumor activity when combined with pd-1 blockade
publisher	Nature Portfolio
publishDate	2018
url	https://doaj.org/article/fa23d329feb04210ba229907d41699e4
work_keys_str_mv	AT winsonsho pharmacologicinhibitionofproteinphosphatase2aachievesdurableimmunemediatedantitumoractivitywhencombinedwithpd1blockade AT heruiwang pharmacologicinhibitionofproteinphosphatase2aachievesdurableimmunemediatedantitumoractivitywhencombinedwithpd1blockade AT dominicmaggio pharmacologicinhibitionofproteinphosphatase2aachievesdurableimmunemediatedantitumoractivitywhencombinedwithpd1blockade AT johnskovach pharmacologicinhibitionofproteinphosphatase2aachievesdurableimmunemediatedantitumoractivitywhencombinedwithpd1blockade AT qizhang pharmacologicinhibitionofproteinphosphatase2aachievesdurableimmunemediatedantitumoractivitywhencombinedwithpd1blockade AT qisong pharmacologicinhibitionofproteinphosphatase2aachievesdurableimmunemediatedantitumoractivitywhencombinedwithpd1blockade AT francescommarincola pharmacologicinhibitionofproteinphosphatase2aachievesdurableimmunemediatedantitumoractivitywhencombinedwithpd1blockade AT johndheiss pharmacologicinhibitionofproteinphosphatase2aachievesdurableimmunemediatedantitumoractivitywhencombinedwithpd1blockade AT markrgilbert pharmacologicinhibitionofproteinphosphatase2aachievesdurableimmunemediatedantitumoractivitywhencombinedwithpd1blockade AT rongzelu pharmacologicinhibitionofproteinphosphatase2aachievesdurableimmunemediatedantitumoractivitywhencombinedwithpd1blockade AT zhengpingzhuang pharmacologicinhibitionofproteinphosphatase2aachievesdurableimmunemediatedantitumoractivitywhencombinedwithpd1blockade
_version_	1718380099371270144

Pharmacologic inhibition of protein phosphatase-2A achieves durable immune-mediated antitumor activity when combined with PD-1 blockade

Ejemplares similares